<DOC>
	<DOCNO>NCT02295891</DOCNO>
	<brief_summary>Primary hyperhidrosis pathological condition characterize idiopathic excessive secretion sweat beyond normal physiological demand localize particular focus face , axilla , palm hand , sole foot . Patients seek medical attention hyperhidrosis often report disruption professional and/or social life due sweat subsequently experience many psychosocial difficulty , anxiety , social phobia , depression . Therefore , psychiatric explanation causality frequently offer patient diagnosis . Excessive sweating often mistakenly interpreted symptom anxiety disorder cause social embarrassment , exacerbate emotional stress social avoidance . As currently constitute , treatment secondary psychosocial symptom primary hyperhidrosis poorly understood require investigation .</brief_summary>
	<brief_title>Miradry Treatment Focal Axillary Hyperhidrosis</brief_title>
	<detailed_description>Primary Objective : 1 . To evaluate effectiveness miraDry 速 treatment system psychosocial functioning patient heavily affect axillary hyperhidrosis . Secondary Objectives : 2 . To characterize outcomes clinical response MiraDry 速 treatment system respect aforementioned criterion . 3 . To compare result non-invasive miraDry 速 treatment system exist surgical correction respect aforementioned criterion .</detailed_description>
	<mesh_term>Hyperhidrosis</mesh_term>
	<criteria>This study recruit patient diagnose focal hyperhidrosis know diagnosis primarily axillary localization . We enroll patient available treatment visit . Availability followup visit optional . Only patient age 18 29 year first HHIQ administer eligible . The upper age limit determine patient 29 year often present psychopathology far recalcitrant correction kind regardless effectiveness duration condition . The low age limit determine 18 year age miraDry 速 procedure approve use FDA . All participant screen use Hyperhidrosis Disease Severity Scale ( HDSS ) . Only patient report condition 3 4 high HDSS eligible study preliminary data suggests effective detection psychological change higher report level sweat severity . A patient 's previous noninvasive treatment course , include limited prescription psychiatric medication topical therapy , justify exclusion study . Patients unable provide inform consent , know allergy lidocaine , hibiclens 4 % chlorhexidine , and/or epinephrine , pregnant ( determined selfreporting ) , unable take oral antibiotic antiseptic wash , heart pacemaker electronic device implant , need supplemental oxygen eligible participate study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>29 Years</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>